Hrvatska znanstvena Sekcija img
3 gif
 O projektu
4 gif
Pregledavanje radova
Jednostavno pretraživanje
Napredno pretraživanje
Skupni podaci
Upis novih radova
Ispravci prijavljenih radova
Ostale bibliografije
Slični projekti
 Bibliografske baze podataka

Pregled bibliografske jedinice broj: 457656


Autori: Duvnjak, Marko; Gomerčić, Marija; Tomašić, Vedran; Smirčić Duvnjak, Lea; Baršić, Neven; Lerotić, Ivan
Naslov: Therapy of nonalcoholic fatty liver disease : current status
Izvornik: Journal of physiology and pharmacology (0867-5910) 60 (2009), S7; 57-66
Vrsta rada: pregledni rad
Ključne riječi: nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; treatment; obesity; metformin; thiazolidinediones; fenofibrate; statins; angiotensin receptor blockers; ursodeoxycholic acid; vitamin E; polyunsaturated fatty acids
Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, has become a common entity in clinical practice. In most of the patients it presents as simple steatosis with nonprogressive clinical course. However, some patients have progressive form of NAFLD, nonalcoholic steatohepatitis (NASH), and are at increased risk of developing cirrhosis and hepatocellular carcinoma. NAFLD treatment includes lifestyle modifications and pharmacotherapy aiming at increasing insulin sensitivity, and attenuating inflammation and hepatic fibrosis. Weight reduction has consistently been shown to reduce levels of liver enzymes and insulin resistance. Although dietary intervention and exercise remain the first-line therapy, due to low patients compliance to these measures pharmacotherapy or surgical approaches are often required. Metformin and thiazolidinediones may improve insulin sensitivity, serum aminotransferase level and liver histology. However, little evidence exists regarding their sustained effects after drug discontinuation which, together with their side effects, limits their widespread use in clinical practice. Statins appear to be safe agents for the treatment of hyperlipidemia, although trials documenting their efficacy in NAFLD are scarce. Based on the recent clinical trials, weight loss medication orlistat, ursodeoxycholic acid and antioxidant agents could potentially be used as adjunctive therapy. Considering still largely controversial clinical data regarding pharmacological agents, their high cost and known side-effects, lifestyle modifications at present remain the only essential considerations in the NAFLD treatment
Projekt / tema: 045-1080230-0516
Izvorni jezik: ENG
Rad je indeksiran u
bazama podataka:
Current Contents Connect (CCC)
Science Citation Index Expanded (SCI-EXP) (sastavni dio Web of Science Core Collectiona)
Kategorija: Znanstveni
Znanstvena područja:
Kliničke medicinske znanosti
Puni text rada: 457656.duvnjak.pdf
URL Internet adrese:
URL cjelovitog teksta:
Google Scholar: Therapy of nonalcoholic fatty liver disease : current status
Upisao u CROSBI: (, 31. Ožu. 2010. u 14:42 sati
Rad je prezentiran na skupu 7th International Symposium on Cell/Tissue Injury and Cytoprotection/Organo-protection : Focus on GI Tract, održanom od 09.-11.09.2012., Hawaii.

  Verzija za printanje   za tiskati